My best case scenario (IMO)
#1 Trof gets licensed out with upfront payment and cash payments at various milestones, if it goes to market get a % of sales.
#2 Use cash for special Divvy + development for NNZ-2591 (Depending on if this included or not)
#3 Await further milestones and collect $$
#4 Drug approved collect $$
#5 On going return of equity to shareholders, neu possibly look at new pipeline drugs and trials using excess cash.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.42 |
Change
-0.150(1.03%) |
Mkt cap ! $1.800B | |||
| Open | High | Low | Value | Volume |
| $14.50 | $14.56 | $14.16 | $2.349M | 163.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 94 | $14.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.42 | 1052 | 19 |
View Market Depth
| Last trade - 15.35pm 14/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |